PDCD1 and neoplasm: Nevertheless, to evade immune surveillance, tumor cells release proteins (such as CTLA-4, PD-1, and its ligand PD-L1) that negatively regulate the immune response, so using antibodies to directly block those negative immune regulators (checkpoints) has proved to be an important strategy to enhance immunity against cancer.